AMC-070: Lenalidomide Is Safe and Effective in HIV-Associated Kaposi Sarcoma.
Erin G ReidKelly ShimabukuroPage MooreRichard F AmbinderJack D BuiSemi HanOtoniel Martinez-MazaDirk P DittmerDavid M AboulafiaElizabeth Yu ChiaoToby MaurerRobert BaiocchiRonald MitsuyasuWilliam Wachsmannull nullPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Lenalidomide is active in HIV-KS. The most common adverse events were manageable. With 60% of participants receiving RP2D obtaining a partial response and <10% discontinuing due to adverse events, the response and tolerability to lenalidomide support its use in HIV-KS. See related commentary by Henry and Maki, p. 2485.